Cargando…

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study

BACKGROUND: Affective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s disease (AD). The prevalence of underlying AD lesions in psychiatric diseases is unkn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paquet, Claire, Magnin, Eloi, Wallon, David, Troussière, Anne-Cécile, Dumurgier, Julien, Jager, Alain, Bellivier, Frank, Bouaziz-Amar, Elodie, Blanc, Frédéric, Beaufils, Emilie, Miguet-Alfonsi, Carole, Quillard, Muriel, Schraen, Susanna, Pasquier, Florence, Hannequin, Didier, Robert, Philippe, Hugon, Jacques, Mouton-Liger, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928321/ https://www.ncbi.nlm.nih.gov/pubmed/27357952 http://dx.doi.org/10.1186/s13195-016-0192-z

Ejemplares similares

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
por: Lehmann, Sylvain, et al.
Publicado: (2014)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

PKR involvement in Alzheimer’s disease
por: Hugon, Jacques, et al.
Publicado: (2017)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model
por: Mouton-Liger, F, et al.
Publicado: (2015)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Are ketogenic diets promising for Alzheimer’s disease? A translational review
por: Lilamand, Matthieu, et al.
Publicado: (2020)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
por: Epelbaum, Stéphane, et al.
Publicado: (2019)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

Peripheral inflammation increases PKR activation, Tau phosphorylation and amyloid β production in wild-type mice
por: Mouton-Liger, François, et al.
Publicado: (2013)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Neuroprotective role of PKR in a model of neurodegeneration due to mild impairment of oxidative metabolism
por: Mouton-Liger, François, et al.
Publicado: (2013)

Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease
por: Chen, Yaohua, et al.
Publicado: (2017)

Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review
por: Lilamand, Matthieu, et al.
Publicado: (2022)

PKR modulates abnormal brain signaling in experimental obesity
por: Taga, Mariko, et al.
Publicado: (2018)

Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?
por: Aveneau, Clément, et al.
Publicado: (2023)

PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions
por: Tible, Marion, et al.
Publicado: (2019)

Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review
por: Indart, Sandrine, et al.
Publicado: (2017)

Neuroinflammation and Aβ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation
por: Carret-Rebillat, Anne-Sophie, et al.
Publicado: (2015)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort
por: Musat, Esteban Munoz, et al.
Publicado: (2021)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer’s disease
por: Rose, Christiane, et al.
Publicado: (2012)

PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease
por: Mouton-Liger, Francois, et al.
Publicado: (2017)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
por: Boza-Serrano, Antonio, et al.
Publicado: (2022)

The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bbc0tibun12jghcqqal9rfctim